Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Conditions: BCL2 Gene Translocation; C-Myc Translocation; Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MY C and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Lymphoma | Prednisone | Research | Rituxan | Translocation